R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting. Pre-clinical data on Medicenna's first-in-class Masked and Tumor Targeted Bifunctional anti- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback